权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Specialized Program Of Research Excellence (SPORE) in Leukemia.

白血病专业卓越研究计划 (SPORE)。

基本信息

批准号：
10194393
负责人：
Daniel C Link
金额：
$ 203.6万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-03 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10194393
关键词：
AML/MDS Acute Lymphocytic Leukemia Acute Myelocytic Leukemia Acute T Cell Leukemia Allogenic Animal Model Antibody Therapy Basic Science Biometry Bispecific Antibodies CD3 Antigens CXCR4 gene Cancer Research Project Clinical Clinical Trials Collaborations Data Decitabine Development Disabled Persons Dysmyelopoietic Syndromes Female Genomics Goals Grant Review Hematopoiesis Immunology Immunotherapy Infrastructure Institution Joints Laboratories Memory Mentors Minority Molecular Molecular Profiling Multi-Institutional Clinical Trial Mutate Mutation Natural Killer Cells Nelarabine Oral Pathway interactions Patients Program Reviews Property RNA Splicing Refractory Relapse Research Research Personnel Research Project Grants Resistance Resources Salvage Therapy Signal Transduction Specialized Program of Research Excellence TP53 gene Testing Therapeutic Therapeutic Trials Training Training Programs Translational Research Universities Washington acute T-cell lymphoblastic leukemia cell antibody conjugate base cancer genomics career conditioning cytokine first-in-human fundamental research hematopoietic cell transplantation inhibitor/antagonist innovation leukemia leukemia treatment meetings mutant novel novel marker novel therapeutics peer pre-clinical preclinical study programs recruit research and development response targeted agent targeted treatment translational cancer research

项目摘要

ABSTRACT The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational research in leukemia. Our long-term goal is to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes and to develop and promote innovative translational leukemia research. To achieve these goals, the following specific aims are proposed. Aim 1. We will exploit institutional expertise in cancer genomics, immunology, and hematopoiesis to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes. Basic research at WUSM has led to the development of the following five translational research projects, all featuring innovative investigator-initiated therapeutic trials for leukemias or MDS. · Project 1. Molecular determinants of decitabine responsiveness · Project 2. Targeted therapies for T cell acute lymphoblastic leukemia (T-ALL) · Project 3. Novel therapies for splicesome-mutant MDS · Project 4. Bi-specific antibody-based therapies for AML · Project 5. Memory-like NK cell augmented hematopoietic cell transplantation for AML Aim 2. We will enhance the infrastructure that supports translational leukemia research. This SPORE will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B. Biostatistics; and 3) Core C. Administration. Aim 3. We will recruit and train new investigators in translational research. This SPORE will support a Career Enhancement Program (CEP) to recruit and mentor new investigators in translational leukemia research. The SPORE has established a successful minority post-baccalaureate training program. The SPORE also will support a Developmental Research Program (DRP) to support innovative translational concepts. Aim 4. We will facilitate inter-SPORE collaboration. Four of the SPORE projects include multi-institutional clinical trials, including three at other Leukemia SPORE institutions. We have established CEP educational exchange and grant review programs with peer Leukemia SPORE institutions. We will continue to organize and participate in joint meetings of Leukemia SPOREs at MD Anderson and Harvard.

摘要